Anticoagulant Therapy in Polytrauma Patients

Initial Assessment and Risk Stratification

The American Society of Clinical Oncology recommends that polytrauma patients with impaired renal function are at high risk for VTE, with renal impairment significantly increasing bleeding risk during anticoagulation therapy, having at least a twofold higher risk compared to patients with normal renal function 2
Assessing creatinine clearance (CrCl) is crucial to determine the degree of renal impairment, with severe renal impairment defined as CrCl <30 mL/min, as suggested by the Journal of Clinical Oncology and The Lancet Oncology 2, 3

The American College of Chest Physicians recommends UFH as the preferred agent in severe renal impairment (CrCl <30 mL/min) due to its shorter half-life 4, hepatic clearance (less dependent on renal elimination) 3, reversibility with protamine sulfate in case of bleeding 5, and better safety profile in severe renal dysfunction [4] [1, 2, 3, 4, 5]
For VTE treatment in severe renal impairment, the recommended initial dose is 80 units/kg IV bolus, with maintenance as a continuous IV infusion of 18 units/kg/hour, and adjusting the dose based on aPTT (target 1.5-2 times normal) 6
Monitoring aPTT every 4-6 hours initially, then at appropriate intervals, is recommended for UFH therapy 4

The American Society of Clinical Oncology suggests that direct oral anticoagulants (DOACs) should be avoided or used with extreme caution in severe renal impairment 2, 6
For patients transitioning to oral anticoagulants, continuing UFH until INR reaches therapeutic range if using vitamin K antagonists is recommended, although the specific details are not provided in the cited references 2, 6
The American College of Chest Physicians recommends considering IVC filter placement in patients with high bleeding risk but critical need for anticoagulation 5, 7

For UFH therapy, monitoring aPTT (target: 1.5-2 times normal) 6, complete blood count with platelets (to monitor for heparin-induced thrombocytopenia) 5, and signs of bleeding is recommended
For LMWH (if used in moderate renal impairment), monitoring anti-Xa levels (4-6 hours after dose) 3, renal function tests 2, and complete blood count with platelets 5 is suggested 2, 4

Avoid using standard doses of LMWH in severe renal impairment as this can lead to bioaccumulation and increased bleeding risk, as warned by the Journal of Clinical Oncology and the Journal of the National Comprehensive Cancer Network 2, 4
The American College of Chest Physicians advises against relying solely on clinical assessment for VTE diagnosis; instead, use appropriate imaging studies 8
Reassessing the need for continued anticoagulation regularly, especially as mobility improves, is recommended by the American College of Chest Physicians 8, 5